Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of August 2021, specifically detailing a registered direct offering announced on August 11, 2021, with an expected closing date of August 16, 2021. The Company, a foreign private issuer based in Israel, entered into a definitive purchase agreement with an institutional investor to raise capital through the issuance of ordinary shares, pre-funded warrants, and unregistered warrants.
Key Financial Metrics and Transaction Details
The filing outlines a capital raise with the following specific terms:
- Gross Proceeds: Approximately $10 million.
- Offering Price: $2.00 per American Depositary Share (ADS) and $1.999 per pre-funded warrant.
- Securities Issued:
- 57,000,000 ordinary shares (represented by 1,900,000 ADSs).
- Pre-funded warrants to purchase 93,000,000 ordinary shares (represented by 3,100,000 ADSs).
- Unregistered warrants to purchase 150,000,000 ordinary shares (represented by 5,000,000 ADSs) at an exercise price of $2.00 per ADS.
- Placement Agent Fees:
- Cash placement fee: 7.0% of aggregate gross proceeds.
- Management fee: 1.0% of aggregate gross proceeds.
- Non-accountable expense allowance: $75,000.
- Clearing expenses: $15,950.
- Placement agent warrants: 7.0% of the aggregate number of ADSs sold (350,000 ADSs) at an exercise price of $2.50 per ADS.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period, as the document focuses exclusively on the terms of the securities offering.
Material Changes and Restrictions
The transaction introduces significant dilution and market restrictions:
- Lock-up Period: The Company agreed not to issue or announce the issuance of any ADSs, ordinary shares, or equivalents for 90 days following the closing, subject to customary exceptions.
- Variable Rate Transaction Restriction: For 13 months following closing, the Company cannot effect a "variable rate transaction," though it may enter into an at-the-market offering facility with H.C. Wainwright & Co., LLC after the initial 90-day period.
- Warrant Terms: Unregistered warrants are immediately exercisable and expire three years after the effectiveness of a resale registration statement. They may be exercised on a cashless basis if no effective registration statement exists.
Outlook, Risks, and Contingencies
Management commentary is limited to the transaction mechanics and standard forward-looking statement warnings.
- Closing Contingency: The offering is expected to close on or about August 16, 2021, but is subject to customary closing conditions. If these are not satisfied, the offering may not close.
- Forward-Looking Statements: The filing explicitly warns that statements regarding the closing date and future intent are not guaranteed and may not occur due to reasons beyond the Company's control.
- Regulatory Status: The warrants and underlying shares are sold pursuant to exemptions from registration requirements (Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D) and are not registered under the Securities Act or applicable state laws.
Investor Verification Checklist
- Verify the actual closing of the offering on or about August 16, 2021, as it is subject to customary conditions.
- Confirm the total dilution impact from the issuance of 1,900,000 ADSs, 3,100,000 pre-funded warrants, and 5,000,000 unregistered warrants.
- Review the specific terms of the 90-day lock-up and 13-month variable rate transaction restrictions to understand future capital raising limitations.
- Assess the impact of the 8.0% total cash fee (7.0% placement + 1.0% management) plus expense allowances on the net proceeds received by the Company.
- Monitor the effectiveness of the resale registration statement required for the exercise of unregistered warrants.